Sample & Assay Technologies - QiagenSample & Assay Technologies Forward looking statements Safe Harbor Statement: Certain of the statements contained in this presentation may be considered

Sample & Assay Technologies

Fourth quarter / Full-year 2012 results

January 30, 2013

Sample & Assay Technologies Forward looking statements

Safe Harbor Statement: Certain of the statements contained in this presentation may be considered forward-looking statementswithin the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities ExchangeAct of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategyor operating results, including without limitation its expected operating results, are forward-looking, such statements are based oncurrent expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but arenot limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations,regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, thecommercial development of markets for our products in applied testing, personalized healthcare, clinical research, proteomics,women's health/HPV testing and nucleic acid-based molecular diagnostics; changing relationships with customers, suppliers andstrategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products(including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); ourability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutionsand producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect ourproducts from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies andbusinesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S.Securities and Exchange Commission (SEC).

Regulation G: Some of the slides in this presentation contain certain summary information about QIAGEN N.V.’s sales, gross profit,operating income, net income, and earnings per share, which information is presented on a “non-GAAP financial measures” basisrather than in accordance with U.S. generally accepted accounting principles (GAAP). Please review QIAGEN’s press releases,which can be found in the Investor Relations section of QIAGEN’s webpage under www.QIAGEN.com, for information on theCompany’s operating income, net income, and earnings per share presented on a GAAP basis. Such GAAP-basis information willalso be contained in the Company’s reports on Form 20-F or Form 6-K to be filed with or furnished to the U.S. Securities andExchange Commission.

2Fourth quarter / Full-year 2012 results

Sample & Assay Technologies Agenda

Fourth quarter / Full-year 2012 results 3

Introduction

Overview Peer Schatz, CEO

Financial results Roland Sackers, CFO

Strategy update Peer Schatz, CEO

Summary Peer Schatz, CEO

2013 outlook Roland Sackers, CFO

Q&A session


Financial results

Q4 2012 review

Q4 and full-year 2012: Overview

Full-year 2012 review

In $ millions(Except EPS) Q4 2012 Q4 2011 Change

$ (CER) FY 2012 FY 2011 Change $ (CER)

Net sales 346.5 334.4+4%

(+4% CER)1,254 1,170

+7%(+10% CER)

Adjusted operating income 106.0 95.6 +11% 356 320 +12%

Adjusted diluted EPS 0.34 0.31 1.08 0.98

2013 perspectives

Accelerating innovation and growth Increase QIAsymphony placements and assay utilization Advance pipeline of >35 molecular diagnostic assay projects Launch QIAGEN’s NGS platform – sample-to-result value proposition Improve efficiency and effectiveness

Challenging comparison due to major product tender in Q4 2011 Higher sales of consumables (+4% CER) and instruments (+7% CER) 31% adjusted operating margin, achieved 1 year ahead of schedule

4

Delivering faster sales and adjusted earnings growth All customer classes and regions support expansion Improving profitability: 28% adjusted operating margin


CER – Constant exchange rates

Sample & Assay Technologies Full-year 2012: All customer classes deliver higher sales


2012 salescontribution ~33% U.S.: ~12%

RoW: ~4% ~8% ~19% ~24%

Change(CER) +33% -8% +22% +5% +1%

Pharma AcademiaAppliedTesting

MDxgrowth drivers

(RoW)

HPV(U.S.)

Rapid growth from Molecular Diagnostics growth drivers and Applied Testing

2012 net sales: $1,254 million (+10% CER)

Molecular Diagnostics Life Sciences

~49% of sales / +15% CER ~ 51% of sales / +5% CER

RoW – Rest of worldCER – Constant exchange rates

Sample & Assay Technologies Full-year 2012: Key results

In $ millions(Except EPS)

FY 2012 FY 2011 Change $ (CER)

Net sales 1,254.5 1,169.7 +7%(+10% CER)

Adjusted gross profit 896.9 832.5 +8%

Adjusted gross profit margin 71% 71%

Adjusted operating income 356.4 319.6 +12%

Adjusted operating income margin 28% 27%

Adjusted tax rate 21% 24%

Adjusted net income 260.7 234.4 +11%

Adjusted EPS 1.08 0.98

Weighted average number of diluted common shares (In millions) 240.7 239.1

CER – Constant exchange ratesFor further information on adjustments, please refer to the reconciliation tables in QIAGEN's Q4 2012 earnings release or appendices.Adjusted net income and adjusted EPS based on net income attributable to owners of QIAGEN N.V.

+6% CER growth from recent acquisitions

Achieved 2012 margin goal, strong finish


In line with 2012 assumptions

Exceeded $1.06 target

Sample & Assay Technologies Full-year 2012: Geographic sales


Asia-Pacific / Japan leads full-year 2012 global performance

34% of total net sales / +9% CER

• Personalized Healthcare• Academia and Pharma• Northern Europe, Nordic• Southern Europe

Europe / Middle East / Africa

Americas


• QuantiFERON-TB• Personalized Healthcare• Applied Testing• Academia and Pharma• HPV (U.S. pricing, Latin America)

Rest of world represents approximately 1% of sales


• Growth in all customer classes• China• Japan Other emerging markets (S. Korea)

Asia-Pacific / Japan



>750 QIAsymphony platforms now placed worldwide Rising number of reagent

rental agreements vs. 2011 Applied Testing leads customer

classes, followed by Pharma and Molecular Diagnostics

Instruments

Full-year 2012: Consumables and instruments

~14%+11% CER

~86% +10% CER

Growth in all customer classes and regions

Expanding leadership in Sample Technologies

New assays in Molecular Diagnostics and Applied Testing

Consumables and other revenues


Q4 2012: Consumables and other revenues +4% CER (~85% of sales), instruments +7% CER (~15% of sales)

Sample & Assay Technologies Q4 2012: Key results

In $ millions(Except EPS)

Q4 2012 Q4 2011 Change $ (CER)

Net sales 346.5 334.4 +4%(+4% CER)

Adjusted gross profit 249.3 229.3 +9%

Adjusted gross profit margin 72% 69%

Adjusted operating income 106.0 95.6 +11%

Adjusted operating income margin 31% 29%

Adjusted tax rate 14% 22%

Adjusted net income 82.8 73.6 +13%

Adjusted EPS 0.34 0.31


CER – Constant exchange ratesFor further information on adjustments, please refer to the reconciliation tables in QIAGEN's Q4 2012 earnings release or appendices.Adjusted net income and adjusted EPS based on net income attributable to owners of QIAGEN N.V.

Q4 2011 results include major HPV tender

Absorbing higher interest expenses and currency losses

Reached target a year ahead of schedule


2012 implementation of tax programs

Higher share price in 2012 affects share count

One-time adverse impact in Q4 2011 from milestone payments

Sample & Assay Technologies $100 million share repurchase program under way

Program amount: Up to $100 million of shares Purchases made on Frankfurt Stock

Exchange and NASDAQ Helps compensate for higher interest expenses

$400 million U.S. private placement in Oct 2012 – very favorable long-term rates

As of December 31, 2012: ~1.9 million shares repurchased Weighted average prices:

EUR 14.05, $18.52

Share repurchase overview

Maintaining strategic flexibility while improving shareholder returns

10

$100 million

~3.1 million shares

Weighted average prices: EUR 14.11, $18.84

Complete program by March 28, 2013


~$57 million

Goal

Repurchased as of January 25, 2013

QIAGEN share repurchase program

Sample & Assay Technologies Full-year 2012: Balance sheet and free cash flow

As of December 31 2012 2011

Group liquidity (In $ millions) 485 276

Net debt (In $ millions) 382 338

Shareholder equity ratio 66% 68%

Net debt / adjusted EBITDA ratio 0.9 0.9

Leverage ratio: Net debt / EBITDA(1)

-0.5

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

2005

(1) Adjusted figures excluding acquisition, integration and restructuring related charges as well as share-based compensation.

Cash flow (In $ millions) 2012 2011

Net operating cash flow 245 245

Purchases of property, plant and equipment -102 -87

Free cash flow 143 158

0.0

3.3

2.2

0.4

-0.1

0.9

2006 2007 2008 2009 2010 2011 2012

0.9

0.2

Healthy financial position offers strategic flexibility to support business expansion


Sample & Assay Technologies Driving innovation and growth in 2012

Initiatives 2012 achievements

Drive platform success

Grow installed instrument base

Exceeded QIAsymphony goal NGS initiative under way Improve HPV automation

Add content Offer new tests across all customer classes

U.S. approvals / EU clearanceRotor-Gene Q PCR cyclertherascreen KRASartus Influenzatherascreen BRAF

Completed U.S. submissionstherascreen EGFRQuantiFERON CMV

New pharma co-development deals >35 assay projects in MDx pipeline Added AmniSure ROM test

Broaden geographicpresence Expand in attractive markets Dynamic growth in top 7 EGM

Grow efficiently and effectively Grow with best-in-class teams

New structure and leadership changes Free up resources to reinvest



2008 End2009

End2010

End2011

End2012

2013

>1,000

QIAsymphony: Unparalleled features driving dissemination of molecular testing

QIAsymphony: Expanding installed base and utilization

Well exceeded 2012 goals >750 installed platforms Double-digit sales growth in consumables Expanding R&D pipeline of new assays

Strong customer demand in all geographic regions


Molecular Diagnostics

Life Sciences

~70% ~30%

>550

>750

Set to exceed 1,000 installed base during 2013

QIAsymphony installed base2012 QIAsymphony achievements

QIAsymphony end-2012 placements

>350

>200

Significant untapped growth opportunities1,200

1,000

800

600

400

200

0

Sample & Assay Technologies Developing several new molecular diagnostic assays

Selected tests in current portfolio Selected potential submissions

Blood Borne VirusHIV

HBV

HCV

HAV

Parvo B19 HEV

Others

Personalized Healthcare

KRAS

EGFR BRAF

JAK2

BCR-ABL

PML-RARa

WT1 IDH1/2

PI3K

ALK

NRAS

JAK2

BCR-ABL

T315I Others

Women’s HealthCT

HSV 1/2

CT/GC HPV M. gen

GBS Trich

Hospital-Acquired Infections

MRSA

C. Diff

VanR

ESBL

Others

TransplantationCMV

EBV

HSV 1/2

VZV

BKV

CMV

HSV 1/2

Other DiseasesM-TB

SARS

Borrelia

WNV

Influenza

Entero

Malaria

Multi Resp


This information is intended to outline QIAGEN’s general product intentions. The development, timing and launch of any of our products aresubject to regulatory approval and remains at our discretion.

Europe (CE-IVD) U.S. (PMA / 510(k) submissions) ASRs (Analyte Specific Reagents)

2125

>35 projects under way

Sample & Assay Technologies QuantiFERON-TB: Expanding range of target customers

Latent tuberculosis (TB)1

Expanding commercial channels to target physicians, military and prisons


1 in 3 people worldwide…

has latent TB

And of those with latent TB…

1 in 10 develop active TB

Latent TB test target groups

Public health TB control

Employmentscreening

Medical staffFire and police

Communityliving

Correctional sitesMilitaryUniversitiesNursing homes

Immunosuppressedpatients

TB risk detection

Clinicaltrials

Patient selection

(1) World Health Organization

Sample & Assay Technologies U.S. KRAS market conversion progressing well

Oncologists demanding therascreen test Designated teams Awareness campaigns NCCN guidelines Medical Advisory Board


~ 110,000

~ 75,000

~ 45,000

Expansionopportunities

End-2012QIAGEN share1

U.S. colorectal cancer patients(Eligible for KRAS testing)

Establishing therascreen brand for wave of companion diagnostics

Complementary U.S. market conversion initiatives

Labs promoting therascreen test Drive test adoption Co-marketing programs Sales training Future tests on platformCurrent

KRAStesting

(1) Annualized estimate

Leading U.S. cancer diagnostics company joins growing list of labs switching to FDA-approved tests

Offers network of >2,000 pathologists Co-marketing, reimbursement services and on-site

validation

Clarient Diagnostics adopts therascreen KRAS test


Lung

Colon

Breast

Pancreas

Prostate

~53,000

~160,000

Preparing for U.S. approval of therascreen EGFR assay

Companion diagnostic paired with afatinib(Boehringer Ingelheim) Submitted for FDA approval in EGFR

mutation-positive advanced NSCLC patients Target action date: Q3 2013 (priority review)

~200,000 new U.S. lung cancer patients annually About 85% of patients have NSCLC

(non-small cell lung cancer)


2013 goal: Expand therascreen U.S. portfolio with EGFR companion diagnostic

therascreen EGFR U.S. submission in late 20122012 U.S. estimated cancer deaths(1)

(1) American Cancer Society. Cancer Facts & Figures 2012NSCLC – Non-small cell lung cancer

~160,000

~39,000

~38,000

~25,000

Sample & Assay Technologies Strengthening leadership team

Dr. Tadd S. Lazarus Chief Medical Officer

Leading QIAGEN’s global medical strategy

Advancing diagnostic portfolio strategy Direct responsibility for

infectious diseases, STIs and women’s health

Strengthening relations with key opinion leaders

Joined in January 2013, formerly with Gen-Probe and Roche

Dr. Masae KawamuraSenior DirectorScientific and Medical Affairs

Portfolio development in TB management

Joined in 2012, formerly with Cellestis and San Francisco Public Health Dept

Dr. Hélène Peyro-Saint-PaulChief Medical Officer QIAGEN Marseille

Cancer biomarkers and diagnostics portfolio

Strengthening relations with key opinion leaders

Joined in 2011, formerly with Ipsogen, Seronoand Bristol-Myers Squibb



2013 goals

Accelerate organic and strategic growth

Expansion through existing portfolio and targeted M&A

Rapid growth from new MDx products U.S. and EU assay submissions New QIAsymphony placements NGS workflow launch Increasing top EGM contribution

Deliver efficiency and effectiveness Optimize resource allocation

Continuous improvement projects New KPIs and reporting system

Employer of choice Best talent and top teams Attracting and retaining top talent Strengthening QIAGEN culture

Enhance customer experience

Exceed customer expectations

New QIAGEN internet site Improving customer satisfaction

2013 goals build on 2012 progress

2013 goals to accelerate innovation and growth


Sample & Assay Technologies Q1 and full-year 2013: Outlook and assumptions

As of January 30, 2013

Q1 2013outlook(4)

FY 2013outlook(4)

Total net sales(1) ~+2-3% CER +5-6% CER

Adjusted diluted EPS(2) ~$0.22-0.23 $1.16-1.18

Share-based compensation (In $ millions) ~6 ~30-32

Amortization of acquired intellectual property (In $ millions) ~30 ~120

Business integration, acquisition and restructuring (In $ millions)(2) ~10-12 ~25-30

Adjusted tax rate(2) ~24% ~20-22%

Weighted average number of fully diluted shares outstanding (Based on $20.00 share price)(3) ~240 million ~240 million

CER – Constant exchange rates(1) Total sales includes contributions from the acquisition of AmniSure (acquired in May 2012) as well as the rest of the QIAGEN business. These expectations do not take into account any

further acquisitions that could be completed in 2013. Does not include impact of potential U.S. sequestration actions under discussion.(2) Adjusted results are non-GAAP financial measures that QIAGEN believes should be considered in addition to the reported results prepared in accordance with generally accepted accounting

principles, but should not be considered a substitute. QIAGEN believes certain items – such as those listed above – should be excluded from adjusted results when they are outside the ongoing core operations, vary from period to period, or affect the comparability of results with its competitors and its own prior periods. For further information on adjustments, please refer to the reconciliation tables in QIAGEN's Q4 2012 earnings release or appendices.

(3) Every $1.00 increase of share price results in ~1 million increase in weighted average number of fully diluted shares outstanding.(4) Adjusted EPS guidance for 2013 includes a net dilution impact of approximately $0.02-0.03 cents per share. This reflects dilution from the start of the U.S. medical device tax as of January

2013 (up to ~$0.02) and higher interest expenses (~$0.02 -0.03) being partially offset by accretion from the share repurchase program (~$0.01 -0.02).



Strong performance in 2012 builds momentum for 2013

Intensifying focus on strategic initiatives

Accelerating innovation and growth in 2013

Exceeded sales and adjusted earnings targets

QIAsymphony driving platform success

Advancing portfolio of >35 molecular diagnostic assay projects

Rapid growth in top emerging markets

Improving efficiency and effectiveness

2013 outlook: Higher sales and adjusted earnings

New product launches support business expansion

Summary



Appendix


In $ millions(unless indicated) FY 2012 FY 2011 Change

Net sales 1,254.5 1,169.7 7%

Net sales (CER) 1,286.0 1,169.7 10%

Gross profit 824.0 749.8 10%

Adjusted gross profit 896.9 832.5 8%

Operating income 169.8 99.6 71%

Adjusted operating income 356.4 319.6 12%

Net income(1) 129.5 96.0 35%

Adjusted net income 260.7 234.4 11%

EPS ($ per share) 0.54 0.40

Adjusted EPS ($ per share) 1.08 0.98


Full-year 2012

Summary income statement

CER – Constant exchange rates(1) Net income in 2011 included a one-time non-cash currency gain recognized in other miscellaneous income in connection with the Cellestis acquisition.For further information on adjustments, please refer to the reconciliation tables in QIAGEN's Q4 2012 earnings release or appendices.Net income and adjusted EPS based on net income attributable to owners of QIAGEN N.V.



In $ millions(unless indicated) Q4 2012 Q4 2011 Change

Net sales 346.5 334.4 4%

Net sales (CER) 349.1 334.4 4%

Gross profit 232.5 201.7 15%

Adjusted gross profit 249.3 229.3 9%

Operating income 48.9 -19.6

Adjusted operating income 106.0 95.6 11%

Net income 38.4 -0.4

Adjusted net income(1) 82.8 73.6 13%

EPS ($ per share) 0.16 0.00

Adjusted EPS ($ per share) 0.34 0.31


Q4 2012

Summary income statement

CER – Constant exchange rates(1) For further information on adjustments, please refer to the reconciliation tables in QIAGEN's Q4 2012 earnings release or appendices.Net income and adjusted EPS based on net income attributable to owners of QIAGEN N.V.


Sample & Assay Technologies Q4 2012: Net sales by customer class


2012 salescontribution ~36% U.S.: ~11%

RoW: ~5% ~7% ~18% ~23%

Change(CER) +25% -21% +16% +1% +0%

Delivering growth against challenging Q4 2011 results with major product tender

Q4 2012 net sales: $347 million (+4% CER)

Molecular Diagnostics Life Sciences

~52% of sales / +6% CER ~ 48% of sales / +2% CER


Pharma AcademiaAppliedTesting

MDxgrowth drivers

(RoW)

HPV(U.S.)

Impacted by major product tender in Q4 2011

Sample & Assay Technologies Full-year 2012

Reconciliation of reported to adjusted figures

In $ millions (Except EPS)

Net sales

Gross profit

Operating income

Pretax income

Incometax

Tax rate

Net income

Diluted EPS(1)

Reported results 1,254.5 824.0 169.8 145.2 -15.6 11% 129.5 0.54

Adjustments

Business integration, acquisition related and restructuring costs

-7.9 46.6 46.5 -13.9 32.8 0.14

Purchased intangibles amortization 78.5 114.6 114.6 -38.7 75.9 0.31

Share-based compensation 2.3 25.4 25.4 -5.6 19.7 0.08

Other non-recurring income and expense -0.4 3.2 2.8 0.01

Total adjustments 72.9 186.6 186.1 -55.0 131.2 0.54

Adjusted results 1,254.5 896.9 356.4 331.3 -70.6 21% 260.7 1.08

(1) In $ using 240.7 million diluted shares Table may have rounding differencesNet income and adjusted EPS based on net income attributable to owners of QIAGEN N.V.


Sample & Assay Technologies Q4 2012

Reconciliation of reported to adjusted figures

In $ millions (Except EPS)

Net sales

Gross profit

Operating income

Pretax income

Incometax

Tax rate

Net income

Diluted EPS(1)

Reported results 346.5 232.5 48.9 38.5 -0.3 1% 38.4 0.16

Adjustments

Business integration, acquisition related and restructuring costs

-3.0 22.4 22.4 -5.5 17.0 0.07

Purchased intangibles amortization 19.3 28.2 28.2 -9.4 18.8 0.08

Share-based compensation 0.5 6.5 6.5 -1.4 5.0 0.02

Other non-recurring income and expense 0.1 3.5 3.6 0.01

Total adjustments 16.8 57.1 57.2 -12.8 44.4 0.18

Adjusted results 346.5 249.3 106.0 95.7 -13.1 14% 82.8 0.34

(1) In $ using 241.8 million diluted shares Table may have rounding differencesNet income and adjusted EPS based on net income attributable to owners of QIAGEN N.V.



2012 adjusted EPS 2013 adjusted EPSoutlook

Full-year 2013 outlook: Adjusted EPS

Includes 2013 net dilution impact of (~$0.02-0.03)

Assumptions

U.S. medical device tax (up to ~$0.02)

Higher interest expenses ($0.02-0.03)

Share repurchase program $0.01-0.02


$1.08

$1.16-1.18

Sample & Assay Technologies Currency impact

In $ millions Q4 2012reported net sales

Net sales at constant exchange rates

(CER)

Net sales change due to currency

Net sales in USD 132.2 132.2

Net sales in EUR 87.7 91.0 -3.3

Net sales in GBP 26.1 25.4 0.7

Net sales in JPY 19.0 20.0 -1.0

Net sales in other currencies 81.5 80.5 1.0

Total 346.5 349.1 -2.6

CER – Constant exchange ratesOther currencies include CAD, TRY, SEK, CHF, AUD, BRL, CNY, MYR, SGD, KRW, HKD, MXN, INR, TWD, RUB

In $ millions FY 2012reported net sales

Net sales at constant exchange rates

(CER)

Net sales change due to currency

Net sales in USD 518.4 518.4

Net sales in EUR 311.2 336.7 -25.5

Net sales in GBP 80.4 80.9 -0.5

Net sales in JPY 68.6 68.6 0.0

Net sales in other currencies 275.9 281.4 -5.5

Total 1,254.5 1,286.0 -31.5


Sample & Assay Technologies Employees as of December 31, 2012

Americas Europe

Asia Pacific / Japan and

rest of worldTotal

Q4 2012Total

Q4 2011 Change

Production 219 695 86 1,000 924 8%

R&D 139 478 53 670 758 -12%

Sales 553 585 462 1,600 1,509 6%

Marketing 60 168 61 289 281 3%

Admin 123 240 77 440 466 -6%

Total 1,094 2,166 739 3,999 3,938 2%


Sample & Assay Technologies QIAGEN trends

2010 2011 2012 2013 estimate

R&D expense (In $ millions) 126 131 122 ~135-140

Capital expenditures (% of net sales)1 11% 10% 10% ~9%

Depreciation (% of net sales) 4% 5% 5% ~5%

Amortization (% of net sales) 9% 9% 11% ~10%


(1) Capital expenditures includes property, plant and equipment and intangibles..

Sample & Assay Technologies List of abbreviations

Adj AdjustedAIV Avian influenza virus ALK Anaplastic Lymphoma KinaseAML1 Acute Lymphoblastic LeukaemiaASR Analyte Specific Reagent AUD Australian DollarBAALC Brain and Acute Leukemia, CytoplasmicBCR-ABL Breakpoint cluster region-abelsonBRAF Serine/Threonine-Protein Kinase B-RafBRL Brazilian RealBKV BK VirusBVDV Bovine virus DiarrheaBVT Blue Tongue Virus C. Diff Clostridium DifficileCAD Canadian Dollar CDx Companion diagnosticsCE European Conformance MarkCER Constant Exchange RatesCHF Swiss Franc CLLU1 Chronic Lymphocytic LeukemiaCMV Cytomegalovirus CNY China Yuan RenminbiCRC Colorectal CancerCSFV Classical Swine Fever VirusCT Chlamydia TrachomatisNG Neisseria GonorrhoeaeDNA Deoxyribonucleic acidEBITDA Earnings before Interest, Taxes, Depreciation

and AmortizationEBV Epstein-Barr virus EGFR Epidermal Growth Factor Receptor

EGM Emerging Growth MarketsEPS Earnings per ShareEU European UnionESBL Extended Spectrum BetaEUR EuroFDA Food and Drug AdministrationFX Foreign Exchange GAAP Generally Accepted Accounting PrinciplesGBP British PoundGBS Group B Streptococcal SepticemiaGMO Genetically Modified OrganismHAV Hepatitis A VirusHBV Hepatitis B Virus HCV Hepatitis C virusHCMV Human cytomegalovirusHEV Hepatitis E VirusHIV Human Immunodeficiency Virus HSV Herpes Simplex VirusHPV Human PapillomavirusHSV 1/2 Herpes Simplex Virus 1 and 2IDH 1/2 Isocitrate Dehydrogenase 1 and 2Ifp Institute for Product QualityIVD In Vitro DiagnosticINR Indian RupeeIP Intellectual PropertyJAK2 Janus Kinase 2JPY Japan YenKRAS Kirsten rat Sarcoma Viral Oncogene Homolog KRW South Korean Won LDT Laboratory Developed TestsMGMT Methylquanine-methyltransferase

Mg/Ms Mycoplasma Mg/MsMDx Molecular DiagnosticsMN1 meningioma 1MP Mycoplasma PneumoniaMRSA Methicillin-Resistant Staphylococcus AureusMTB Mycobacterium TuberculosisMPL Myeloproliferative leukemiaNGS Next Generation Sequencing NPM1 NucleophosminNIH National Institutes of HealthNRAS Neuroblastoma RAS-viralPCR Polymerase chain reactionPI3K Phosphoinostide 3-kinaseR&D Research & DevelopmentRoW Rest of WorldRGQ Rotor-Gene QRNA Ribonucleic Acid ROM Rupture of Fetal MembranesRUO Research Use Only SARS Severe Acute Respiratory SyndromeSBV Schmallenberg Virus VZV Varicella-Zoster Virus TB Tubercles Bacillus Trich TrichomoniasisTRY Turkish New LiraUGT1A1 UDP-glucuronosyltransferase 1-1 UU Ureaplasma UrealyticumWGA Whole Genome AmplificationWT1 Wilms tumor protein


Sample & Assay Technologies Your contacts

E-mail: [email protected]

CalendarQ1 2013 results Media release: April 29, 2013

Conference call: April 30, 2013

Q2 2013 results Media release: July 30, 2013

Conference call: July 31, 2013

Q3 2013 results Media release: October 29, 2013

Conference call: October 30, 2013

Share information

NASDAQ: QGEN

Frankfurt: QIA

ISIN: NL0000240000

WKN: 901626

John GilardiVice President Corporate CommunicationsTel: +49 2103 29 11711

or +1 240 686 2222Mobile: +49 152 018 11711E-mail: [email protected]

Angela SchmidtAssistantInvestor RelationsTel: +49 2103 29 11709Mobile: +49 152 018 11709E-mail: [email protected]

Peter VozzoDirector Global Investor RelationsTel: +1 240 686 7400Mobile: +1 240 751 7182E-mail: [email protected]


Documents

Sample & Assay Technologies - QiagenSample & Assay Technologies Forward looking statements Safe Harbor Statement: Certain of the statements contained in this presentation may be considered